ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®
Berlin, Germany and Bethesda, MD, USA, July 27, 2021: ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application..
Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line
Berlin, Germany, July 13, 2021: ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System..
ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific
Berlin, Germany and Utrecht, Netherlands, June 22, 2021: ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a..
City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and Duarte, USA, June 9, 2021: ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and..
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company
Berlin, Germany and Cairo, Egypt, May 27, 2021: ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin..
ProBioGen und Minapharm Pharmaceuticals gründen die MiGenTra GmbH mit dem Ziel, das Gesundheitswesen zu verändern
Berlin, Deutschland und Kairo, Ägypten, 27. Mai 2021: ProBioGen und Minapharm Pharmaceuticals geben die Gründung von ProBioGens Tochtergesellschaft "MiGenTra" bekannt. Die neue..
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Apr 12, 2023
